TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Eisai
Press Release
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia
Oct 02, 2024 10:28 JST
Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Pharmaceuticals Single Person Limited Liability Company (Eisai Saudi Arabia), a pharmaceutical sales subsidiary recently established in Riyadh in the Kingdom of Saudi Arabia (Saudi Arabia).
More info..
Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis
Sep 24, 2024 15:06 JST
Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing authorization approval for amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin for Injection 25 mg" (mecobalamin) in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis.
More info..
Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements
Sep 24, 2024 14:01 JST
Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements
More info..
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Sep 17, 2024 09:08 JST
These late-breaking data were presented for the first time on September 14 (Central European Summer Time) during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2024 (Presentation #LBA3).
More info..
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
Sep 05, 2024 15:59 JST
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2024, which is taking place virtually and in-person in Barcelona, Spain from September 13 to 17.
More info..
Eisai Announces Status Relating to Acquisition of Own Shares
Sep 02, 2024 14:12 JST
Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act.
More info..
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
Aug 22, 2024 18:54 JST
Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Abeta) monoclonal antibody "Leqembi" (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.
More info..
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
Aug 14, 2024 08:59 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of Alzheimer's disease (AD).
More info..
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
Aug 06, 2024 12:15 JST
Eisai Co., Ltd. reconfirmed that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI (generic name:lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows.
More info..
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024
Jul 31, 2024 12:59 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta (Abeta) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, and virtually.
More info..
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
Jul 29, 2024 16:59 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer?s disease (AD) and mild AD).
More info..
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
Jul 25, 2024 09:30 JST
Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society.
More info..
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
Jul 23, 2024 19:23 JST
The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab.
More info..
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
Jul 12, 2024 11:56 JST
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD).
More info..
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong
Jul 11, 2024 09:00 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD).
More info..
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
Jul 02, 2024 12:01 JST
Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb.
More info..
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China
Jun 28, 2024 14:57 JST
China is the third country to launch LEQEMBI following the United States and Japan.
More info..
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City
Jun 21, 2024 14:35 JST
Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024.
More info..
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jun 10, 2024 17:50 JST
Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing.
More info..
Eisai Named to List of The Time 100 Most Influential Companies
Jun 03, 2024 16:08 JST
TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world.
More info..
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform
Jun 03, 2024 14:22 JST
Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses in the future, so as to accelerate drug discovery innovation and the establishment of the ecosystem platform.
More info..
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
May 28, 2024 14:19 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD).
More info..
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
May 23, 2024 17:07 JST
Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.
More info..
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan
May 22, 2024 11:55 JST
Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan.
More info..
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
May 15, 2024 10:19 JST
LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD).
More info..
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
May 13, 2024 16:06 JST
Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older.
More info..
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 18, 2024 09:53 JST
Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology.
More info..
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 17, 2024 15:17 JST
Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan.
More info..
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Apr 03, 2024 15:24 JST
Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX").
More info..
1
2
3
>>
Last
Latest Release
Honda Announces CUV e: and ICON e: Electric Personal Commuters in Indonesia
Oct 09, 2024 17:46 JST
Mitsubishi Power Completes Landmark 5,300MW Combined Cycle Power Plant Project in Thailand
Oct 09, 2024 17:16 JST
Honda Introduces Next-generation Technologies for Honda 0 Series Models at Honda 0 Tech Meeting 2024
Oct 09, 2024 17:03 JST
Toyota to Exhibit at Japan Mobility Show Bizweek 2024
Oct 09, 2024 14:48 JST
Fujitsu leverages data to secure stable and efficient power supply for Kansai Transmission and Distribution
Oct 09, 2024 11:00 JST
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia
Oct 08, 2024 14:00 JST
JCB and Nuvei expand global partnership in APAC
Oct 08, 2024 12:00 JST
JCB to offer Google Pay(TM) in Japan
Oct 07, 2024 11:00 JST
Fujitsu highlights technologies to realize its vision of AI as a trusted assistant at CEATEC 2024
Oct 04, 2024 11:03 JST
Toyota to Invest $500 Million in Joby Aviation
Oct 03, 2024 15:59 JST
Fujitsu and Supermicro announce strategic collaboration to develop green AI computing technology and liquid-cooled datacenter solutions
Oct 03, 2024 09:38 JST
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia
Oct 02, 2024 11:28 JST
IOWN All-Photonics Network with Optical Fiber Sensing Functions Achieves Wide-Area Traffic Flow Monitoring
Oct 01, 2024 17:44 JST
Release of Mazda Integrated Report 2024
Oct 01, 2024 10:56 JST
DENSO and ROHM Agree to Start Consideration of Strategic Partnership in the Semiconductor Field
Oct 01, 2024 09:27 JST
Olympus Launches VISERA S, a New Imaging Platform
Sep 30, 2024 15:00 JST
Fujitsu launches "Takane" - A large language model for enterprises offering the highest Japanese language proficiency in the world
Sep 30, 2024 14:05 JST
DENSO Announces Changes of Executive Responsibility and Executive Officers
Sep 30, 2024 13:22 JST
Mitsubishi Corporation: JOGMEC Commissioned Feasibility Study for Overseas CCS Value Chain
Sep 30, 2024 11:38 JST
Mazda Production and Sales Results for August 2024
Sep 27, 2024 17:20 JST
More Latest Release >>